PortfoliosLab logoPortfoliosLab logo
KGC vs. AZN
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

KGC vs. AZN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Kinross Gold Corporation (KGC) and AstraZeneca PLC (AZN). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, KGC achieves a -7.93% return, which is significantly lower than AZN's 0.81% return. Over the past 10 years, KGC has outperformed AZN with an annualized return of 18.75%, while AZN has yielded a comparatively lower 15.85% annualized return.


KGC

1D
-1.37%
1M
-17.82%
YTD
-7.93%
6M
-2.01%
1Y
72.32%
3Y*
76.89%
5Y*
29.50%
10Y*
18.75%

AZN

1D
-2.37%
1M
-0.71%
YTD
0.81%
6M
1.53%
1Y
28.04%
3Y*
9.54%
5Y*
12.08%
10Y*
15.85%
*Multi-year figures are annualized to reflect compound growth (CAGR)

KGC vs. AZN - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
KGC
Kinross Gold Corporation
-7.93%206.11%55.63%51.83%-27.59%-19.00%56.04%46.30%-25.00%38.91%
AZN
AstraZeneca PLC
0.81%43.30%-0.62%1.44%19.14%19.66%3.12%35.68%13.86%33.10%

Correlation

The correlation between KGC and AZN is 0.17, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.17

Correlation (3Y)
Calculated over the trailing 3-year period

0.18

Correlation (5Y)
Calculated over the trailing 5-year period

0.21

Correlation (10Y)
Calculated over the trailing 10-year period

0.15

Correlation (All Time)
Calculated using the full available price history since Oct 20, 1994

0.12

Fundamentals

Market Cap

KGC:

$31.14B

AZN:

$283.40B

EPS

KGC:

$2.35

AZN:

$6.66

PE Ratio

KGC:

10.99

AZN:

27.27

PEG Ratio

KGC:

0.15

AZN:

0.04

PS Ratio

KGC:

3.96

AZN:

4.69

PB Ratio

KGC:

3.41

AZN:

5.99

Total Revenue (TTM)

KGC:

$7.94B

AZN:

$60.44B

Gross Profit (TTM)

KGC:

$4.19B

AZN:

$49.37B

EBITDA (TTM)

KGC:

$5.02B

AZN:

$20.47B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

KGC vs. AZN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KGC
KGC Risk / Return Rank: 7878
Overall Rank
KGC Sharpe Ratio Rank: 8181
Sharpe Ratio Rank
KGC Sortino Ratio Rank: 7373
Sortino Ratio Rank
KGC Omega Ratio Rank: 7676
Omega Ratio Rank
KGC Calmar Ratio Rank: 7878
Calmar Ratio Rank
KGC Martin Ratio Rank: 8080
Martin Ratio Rank

AZN
AZN Risk / Return Rank: 7373
Overall Rank
AZN Sharpe Ratio Rank: 7575
Sharpe Ratio Rank
AZN Sortino Ratio Rank: 7373
Sortino Ratio Rank
AZN Omega Ratio Rank: 6969
Omega Ratio Rank
AZN Calmar Ratio Rank: 7474
Calmar Ratio Rank
AZN Martin Ratio Rank: 7676
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

KGC vs. AZN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Kinross Gold Corporation (KGC) and AstraZeneca PLC (AZN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


KGCAZNDifference
Sharpe ratioReturn per unit of total volatility

+0.32

Sortino ratioReturn per unit of downside risk

+0.01

Omega ratioGain probability vs. loss probability

1.26

1.21

+0.05

Calmar ratioReturn relative to maximum drawdown

2.28

1.83

+0.45

Martin ratioReturn relative to average drawdown

6.11

4.90

+1.21

KGC vs. AZN - Sharpe Ratio Comparison

The current KGC Sharpe Ratio is 1.43, which is comparable to the AZN Sharpe Ratio of 1.11. The chart below compares the historical Sharpe Ratios of KGC and AZN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


KGCAZNDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.43

1.11

+0.32

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.67

0.51

+0.17

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.40

0.64

-0.24

Sharpe Ratio (All Time)

Calculated using the full available price history

0.08

0.49

-0.42

Drawdowns

KGC vs. AZN - Drawdown Comparison

The maximum KGC drawdown since its inception was -96.00%, which is greater than AZN's maximum drawdown of -48.94%. Use the drawdown chart below to compare losses from any high point for KGC and AZN.


Loading charts...

Drawdown Indicators


KGCAZNDifference

Max Drawdown

Largest peak-to-trough decline

-96.00%

-48.94%

-47.06%

Max Drawdown (1Y)

Largest decline over 1 year

-31.89%

-15.43%

-16.46%

Max Drawdown (3Y)

Largest decline over 3 years

-31.89%

-27.87%

-4.02%

Max Drawdown (5Y)

Largest decline over 5 years

-60.31%

-27.87%

-32.44%

Max Drawdown (10Y)

Largest decline over 10 years

-67.75%

-27.87%

-39.88%

Current Drawdown

Current decline from peak

-31.89%

-12.90%

-18.99%

Average Drawdown

Average peak-to-trough decline

-57.62%

-11.37%

-46.25%

Ulcer Index

Depth and duration of drawdowns from previous peaks

11.88%

5.75%

+6.13%

Volatility

KGC vs. AZN - Volatility Comparison

Kinross Gold Corporation (KGC) has a higher volatility of 16.41% compared to AstraZeneca PLC (AZN) at 7.42%. This indicates that KGC's price experiences larger fluctuations and is considered to be riskier than AZN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


KGCAZNDifference

Volatility (1M)

Calculated over the trailing 1-month period

16.41%

7.42%

+8.99%

Volatility (6M)

Calculated over the trailing 6-month period

39.75%

17.47%

+22.28%

Volatility (1Y)

Calculated over the trailing 1-year period

50.78%

25.55%

+25.23%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

44.07%

24.02%

+20.05%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

46.95%

24.94%

+22.01%

Dividends

KGC vs. AZN - Dividend Comparison

KGC's dividend yield for the trailing twelve months is around 0.56%, less than AZN's 2.93% yield.


PositionTTM20252024202320222021202020192018201720162015
AZN
AstraZeneca PLC
2.93%1.70%2.27%2.15%2.12%2.35%2.80%2.81%3.69%3.95%5.01%4.06%
KGC
Kinross Gold Corporation
0.56%0.44%1.29%1.98%2.93%2.69%0.82%0.00%0.00%0.00%0.00%0.00%

Financials

KGC vs. AZN - Financials Comparison

This section allows you to compare key financial metrics between Kinross Gold Corporation and AstraZeneca PLC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00B10.00B15.00B20222023202420252026
2.37B
15.29B
(KGC) Total Revenue
(AZN) Total Revenue
Values in USD except per share items

KGC vs. AZN - Profitability Comparison

The chart below illustrates the profitability comparison between Kinross Gold Corporation and AstraZeneca PLC over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%20222023202420252026
57.8%
82.5%
Portfolio components
KGC - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Kinross Gold Corporation reported a gross profit of 1.37B and revenue of 2.37B. Therefore, the gross margin over that period was 57.8%.

AZN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a gross profit of 12.61B and revenue of 15.29B. Therefore, the gross margin over that period was 82.5%.

KGC - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Kinross Gold Corporation reported an operating income of 1.31B and revenue of 2.37B, resulting in an operating margin of 55.1%.

AZN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported an operating income of 4.25B and revenue of 15.29B, resulting in an operating margin of 27.8%.

KGC - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Kinross Gold Corporation reported a net income of 831.32M and revenue of 2.37B, resulting in a net margin of 35.0%.

AZN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a net income of 3.08B and revenue of 15.29B, resulting in a net margin of 20.2%.


Frequently Asked Questions


KGC and AZN have a correlation of 0.17, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

KGC has higher volatility (16.41%) compared to AZN (7.42%). In terms of maximum drawdown, KGC dropped -96.00% vs AZN's -48.94%.

KGC currently has the higher Sharpe Ratio (1.43 vs 1.11), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for KGC and AZN

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer